NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $101.60 -0.35 (-0.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$100.17 -1.43 (-1.41%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeneDx alerts:Sign Up Key Stats Today's Range$97.89▼$103.4250-Day Range$64.04▼$103.5152-Week Range$25.32▼$117.75Volume835,293 shsAverage Volume967,633 shsMarket Capitalization$2.90 billionP/E Ratio2,032.00Dividend YieldN/APrice Target$100.38Consensus RatingModerate Buy Company Overview GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 60% of companies evaluated by MarketBeat, and ranked 379th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 4 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth115.46% Earnings GrowthEarnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is 2,032.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.12.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is 2,032.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.88.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 10.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.98% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently decreased by 6.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.98% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently decreased by 6.20%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.69 News SentimentGeneDx has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 36 news articles for GeneDx this week, compared to 9 articles on an average week.Search Interest9 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have bought 168.63% more of their company's stock than they have sold. Specifically, they have bought $5,601,000.00 in company stock and sold $2,085,051.00 in company stock.Percentage Held by Insiders29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address WGS Stock News HeadlinesGeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $40,860.28 in StockAugust 1 at 6:26 AM | insidertrades.comKatherine Stueland Sells 3,220 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockJuly 12, 2025 | insidertrades.comMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off. | American Alternative (Ad)Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $122,465.28 in StockJuly 4, 2025 | insidertrades.comWGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. ...August 2 at 1:17 PM | gurufocus.comWGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your RightsAugust 2 at 12:52 PM | globenewswire.comWells Fargo & Company Forecasts Strong Price Appreciation for GeneDx (NASDAQ:WGS) StockAugust 2 at 2:07 AM | americanbankingnews.comGeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End GrowthJuly 31 at 3:48 PM | seekingalpha.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $76.86 at the start of the year. Since then, WGS stock has increased by 32.2% and is now trading at $101.60. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) issued its quarterly earnings data on Tuesday, July, 29th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.10 by $0.40. The company had revenue of $102.69 million for the quarter, compared to analyst estimates of $86 million. GeneDx had a trailing twelve-month return on equity of 16.51% and a net margin of 0.39%. Read the conference call transcript. When did GeneDx's stock split? GeneDx's stock reverse split before market open on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? Top institutional investors of GeneDx include William Blair Investment Management LLC (5.72%), Jennison Associates LLC (1.39%), Gagnon Securities LLC (0.95%) and Aberdeen Group plc (0.48%). Insiders that own company stock include Casdin Capital, Llc, Keith A Meister, School Of Medicine At Mo Icahn, Opko Health, Inc, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Isaac Ro, Karen Ann White, Kevin Feeley, Katherine Stueland and Richard Miao. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings7/29/2025Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Price Target for GeneDx$100.38 High Price Target$118.00 Low Price Target$80.00 Potential Upside/Downside-1.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.05 Trailing P/E Ratio2,032.00 Forward P/E Ratio104.74 P/E GrowthN/ANet Income-$52.29 million Net Margins0.39% Pretax Margin0.42% Return on Equity16.51% Return on Assets9.35% Debt Debt-to-Equity Ratio0.19 Current Ratio2.87 Quick Ratio3.07 Sales & Book Value Annual Sales$305.45 million Price / Sales9.49 Cash Flow$1.02 per share Price / Cash Flow99.29 Book Value$9.71 per share Price / Book10.46Miscellaneous Outstanding Shares28,530,000Free Float20,087,000Market Cap$2.90 billion OptionableOptionable Beta2.02 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:WGS) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.